ISSN 0253-2778

CN 34-1054/N

Open AccessOpen Access JUSTC

Advances on EGFR-TKIs and acquired resistance mechanisms in non-small cell lung cancer

Cite this:
https://doi.org/10.3969/j.issn.0253-2778.2018.10.003
  • Received Date: 18 July 2018
  • Rev Recd Date: 05 September 2018
  • Publish Date: 31 October 2018
  • Nowadays, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. However, acquired drug resistance remains an unavoidable bottleneck in clinical application. Herein, the mechanisms of acquired drug resistance were reviewed first, including secondary mutation of EGFR, amplification of MET gene, IGF1R and amplification of HER2. Then, therapeutic
    Nowadays, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. However, acquired drug resistance remains an unavoidable bottleneck in clinical application. Herein, the mechanisms of acquired drug resistance were reviewed first, including secondary mutation of EGFR, amplification of MET gene, IGF1R and amplification of HER2. Then, therapeutic
  • loading
  • 加载中

Catalog

    Article Metrics

    Article views (183) PDF downloads(390)
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return